Access the full text.
Sign up today, get DeepDyve free for 14 days.
G Neumann, T Watanabe, H Ito, S Watanabe, H Goto (1999)
Generation of influenza A viruses entirely from cloned cDNAsProc Natl Acad Sci USA, 96
S Hatakeyama, Y Sakai-Tagawa, M Kiso, H Goto, C Kawakami (2005)
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitorJ Clin Microbiol, 43
M Ozawa, Y Kawaoka (2011)
Taming influenza virusesVirus Resh, 162
R Uraki, M Kiso, K Iwatsuki-Horimoto, S Fukuyama, E Takashita (2013)
A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challengesJ Virol, 87
A Moghaddam, W Olszewska, B Wang, JS Tregoning, R Helson (2006)
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccinesNat Med, 12
J Chang (2011)
Current progress on development of respiratory syncytial virus vaccineBMB Rep, 44
GP Bembridge, N Rodriguez, R Garcia-Beato, C Nicolson, JA Melero (2000)
Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) proteinVaccine, 19
PJ Openshaw, SL Clarke, FM Record (1992)
Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein GInt Immunol, 4
HW Kim, JG Canchola, CD Brandt, G Pyles, RM Chanock (1969)
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccineAm J Epidemiol, 89
M Grimaldi, B Gouyon, P Sagot, C Quantin, F Huet (2007)
Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasiaPediatr Pulmonol, 42
GP Bembridge, JA Lopez, R Cook, JA Melero, G Taylor (1998)
Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferonJ Virol, 72
RA Olmsted, N Elango, GA Prince, BR Murphy, PR Johnson (1986)
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunityProc Natl Acad Sci USA, 83
SC Brock, JM Heck, PA McGraw, JE Crowe (2005)
The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequenceJ Virol, 79
WW Stevens, J Sun, JP Castillo, TJ Braciale (2009)
Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced diseaseViral Immunol, 22
SR Singh, VA Dennis, CL Carter, SR Pillai, A Jefferson (2007)
Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse modelVaccine, 25
W Olszewska, Y Suezer, G Sutter, PJ Openshaw (2004)
Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteinsVaccine, 23
A Boelen, A Andeweg, J Kwakkel, W Lokhorst, T Bestebroer (2000)
Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged miceVaccine, 19
MF Delgado, S Coviello, AC Monsalvo, GA Melendi, JZ Hernandez (2009)
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseNat Med, 15
GA Prince, AB Jenson, VG Hemming, BR Murphy, EE Walsh (1986)
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virusJ Virol, 57
MP Girard, T Cherian, Y Pervikov, MP Kieny (2005)
A review of vaccine research and development: human acute respiratory infectionsVaccine, 23
M Barends, M Oosten, CG Rond, JA Dormans, AD Osterhaus (2004)
Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammationJ Infect Dis, 189
GP Bembridge, N Rodriguez, R Garcia-Beato, C Nicolson, JA Melero (2000)
DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammationJ Gen Virol, 81
M Ozawa, ST Victor, AS Taft, S Yamada, C Li (2011)
Replication-incompetent influenza A viruses that stably express a foreign geneJ Gen Virol, 92
GP Bembridge, JA Lopez, R Bustos, JA Melero, R Cook (1999)
Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challengeJ Virol, 73
RB DuBridge, P Tang, HC Hsia, PM Leong, JH Miller (1987)
Analysis of mutation in human cells by using an Epstein–Barr virus shuttle systemMol Cell Biol, 7
T Horimoto, S Murakami, Y Muramoto, S Yamada, K Fujii (2007)
Enhanced growth of seed viruses for H5N1 influenza vaccinesVirology, 366
LM Haynes, LP Jones, A Barskey, LJ Anderson, RA Tripp (2003)
Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C–CX3CR1 interaction and expression of substance PJ Virol, 77
EA Kurt-Jones, L Popova, L Kwinn, LM Haynes, LP Jones (2000)
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virusNat Immunol, 1
H Niwa, K Yamamura, J Miyazaki (1991)
Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 108
H Kida, LE Brown, RG Webster (1982)
Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virusVirology, 122
HF Rosenberg, KD Dyer, JB Domachowske (2009)
Respiratory viruses and eosinophils: exploring the connectionsAntiviral Res, 83
ST Victor, S Watanabe, H Katsura, M Ozawa, Y Kawaoka (2012)
A replication-incompetent PB2-knockout influenza A virus vaccine vectorJ Virol, 86
C Xie, JS He, M Zhang, SL Xue, Q Wu (2007)
Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimuriumHum Gene Ther, 18
Y Becker (2006)
Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy–a reviewVirus Genes, 33
J Schwarze, E Hamelmann, KL Bradley, K Takeda, EW Gelfand (1997)
Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergenJ Clin Invest, 100
PF Wright, G Neumann, Y Kawaoka (2007)
Fields virology
R Kohlmann, S Schwannecke, B Tippler, N Ternette, VV Temchura (2009)
Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virusJ Virol, 83
LM Haynes, DD Moore, EA Kurt-Jones, RW Finberg, LJ Anderson (2001)
Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virusJ Virol, 75
HY Shao, SL Yu, C Sia, Y Chen, E Chitra (2009)
Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenovirusesVaccine, 27
Infections with influenza and respiratory syncytial virus (RSV) rank high among the most common human respiratory diseases worldwide. Previously, we developed a replication-incompetent influenza virus by replacing the coding sequence of the PB2 gene, which encodes one of the viral RNA polymerase subunits, with that of a reporter gene. Here, we generated a PB2-knockout recombinant influenza virus expressing the F protein of RSV (PB2-RSVF virus) and tested its potential as a bivalent vaccine. In mice intranasally immunized with the PB2-RSVF virus, we detected high levels of antibodies against influenza virus, but not RSV. PB2-RSVF virus-immunized mice were protected from a lethal challenge with influenza virus but experienced severe body weight loss when challenged with RSV, indicating that PB2-RSVF vaccination enhanced RSV-associated disease. These results highlight one of the difficulties of developing an effective bivalent vaccine against influenza virus and RSV infections.
Archives of Virology – Springer Journals
Published: May 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.